Aficamten 10mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Aficamten
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Aficamten
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Aficamten on the MHRA register
Myqorzo 10mg tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 16 · Randomised trials: 4 · 2021–2026
Showing the 50 most relevant studies, sorted by most relevant.
Ayesha Aman, Arfa Akram, Bisma Akram, et al.
Open Heart, 2025
- Benzylamines
- Cardiomyopathy, Hypertrophic
- Uracil
BACKGROUND: Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes. This meta-analysis sought to determine the efficacy of mavacamten and aficamten in hypertrophic cardiomyopathy. METHODS: The online databases were searched from inception to July 2024, including the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, ClinicalTrials.gov. The meta-analytical data were pooled using risk ratios (RRs) with 95% CI, standard mean difference (SMD) and SE. RESULTS: A total of 6 randomised controlled trials with 826 hypertrophic cardiomyopathy patients (mean age±SD up to 59.8±14.2 years in intervention vs 60.9±10.5 years in placebo) were included in our study. Of these, 443 received a cardiac myosin inhibitor and 383 received a placebo. The resting left ventricular outflow tract (LVOT) gradient between the two groups was considerably improved by cardiac myosin inhibitors (MD -57.27; 95% CI -63.05 to -51.49). Significant differences were also observed in the post-Valsalva LVOT gradient between the two groups (MD -55.86; 95% CI -65.55 to -46.18). Significantly decreased left ventricle ejection fraction (LVEF) was also seen (MD -4.74; 95% CI -7.22 to -2.26). The New York Health Association (NYHA) class improvement between the two groups also changed significantly (RR 2.21; 95% CI 1.75 to 2.80). Cardiac myosin inhibitors also caused significant improvement in the Kansas City Cardiomyopathy Questionnaire in a Clinical Summary Score between the two groups (MD 7.71; 95% CI 5.37 to 10.05) and significant reduction in the N-terminal pro-B-type natriuretic peptide (SMD -13.27; 95% CI -17.51 to -9.03) and the cardiac troponin I (SMD -11.90; 95% CI -15.07 to -8.72). CONCLUSION: According to our meta-analysis, cardiac myosin inhibitors significantly improve the resting and post-Valsalva LVOT gradient, reduce the LVEF and improve the NYHA class and cardiac biomarkers when compared with the placebo. PROSPERO REGISTRATION NUMBER: CRD52024586161.
Abstract licence: CC BY-NC 4.0
Muhammad Nabeel Saddique, Hamza Irfan, Saad Ashraf, et al.
American Heart Journal Plus: Cardiology Research and Practice, 2025
Hasana U, Korpal M, Haider F, et al.
Annals of medicine and surgery (2012), 2025
Background/objectiveHCM is a structural disorder of the myocardium that leads to sudden cardiac death in young adults. We synthesized an updated understanding of the role of Cardiac Myosin Inhibitors (CMIs) in HCM by pooling data from RCTs.MethodsWe identified six published RCTs, involving 826 participants. Data were extracted pertaining to study characteristics; primary outcomes of interest-(1) change from baseline in resting left ventricular outflow tract (LVOT) peak gradient, (2) change from baseline in Valsalva LVOT peak gradient, and (3) improvement of ≥1 NYHA class-and secondary outcomes. These were pooled using Review Manager 5.4, employing a random-effects model, and reported as odds ratios (ORs) or mean differences (MDs).ResultsWe found statistically significant between-group difference favoring CMIs in change from baseline in LVOT peak gradient: at rest (MD -39.33; -53.01 to -25.64), post-Valsalva (MD -48.99; -53.96 to -44.03), and post-exercise (MD -37.11; -44.34 to -29.87); ≥1 NYHA class improvement (OR 4.10; 2.79-6.02), change from baseline in peak oxygen uptake (MD -37.11; -44.34 to -29.87), LVOT gradient ≤30 mm hg (RR 14.89; 7.47-29.67), participants eligible for septal reduction therapy (RR 0.26; 0.18-0.36), and change from baseline in KCCQ-CSS score (MD 8.54; 5.36-11.71). Subgrouping by intervention type (mavacamten vs. aficamten) revealed non-significant results for all primary outcomes.ConclusionsCMIs can contribute to improving key efficacy outcomes for patients with HCM while reducing incidence of SRT.
Abstract licence: CC BY-NC-SA
Adarsh Raja, Hafsah Alim Ur Rahman, Muhammad Ahmed, et al.
American Journal of Therapeutics, 2024
Md Fahim, Daoud Eldawud, Omar Wahadneh, et al.
The American Journal of Cardiology, 2026
- Benzylamines
- Cardiomyopathy, Hypertrophic
- Tropomyosin
Ayesha Aman, Bisma Akram, Arfa Akram, et al.
2025
Syeda Beenish Bareeqa, Syed Hasham Humayun, Maninder Singh, et al.
Journal of Cardiac Failure, 2026
Muhammad Ibrahim, Aamna Kashif, S M Washaqul Arfin, et al.
Critical Pathways in Cardiology A Journal of Evidence-Based Medicine, 2026
- Benzylamines
- Cardiomyopathy, Hypertrophic
- Uracil
Martin S. Maron, Ahmad Masri, Michael E. Nassif, et al.
New England Journal of Medicine, 2024
- Cardiomyopathy, Hypertrophic
- Cardiovascular Agents
- Exercise Test
Martin S. Maron, Ahmad Masri, Lubna Choudhury, et al.
Journal of the American College of Cardiology, 2023
- Cardiomyopathy, Hypertrophic
- Heart Failure
- Ventricular Outflow Obstruction
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
80 hours
Mechanism
Aficamten is an oral, selective, and allosteric cardiac myosin inhibitor designe…
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1 mg
Half-life
80 hours
[L54788]
Protein binding
90%
[L54788]
Volume of distribution
313 L
[L54788]
Metabolism
56%
Elimination
20 mg
Clearance
2.6 L/h
[L54788]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L54788]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 456 interactions
[L54788]
Beyond hemodynamic changes, aficamten induces favorable cardiac remodeling. A cardiac magnetic resonance (CMR) substudy demonstrated significant reductions in left ventricular mass index, maximal wall thickness, and left atrial volume index after 24 weeks of treatment, alongside substantial declines in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I.[A275293][A275298][A275308] Consistent with its mechanism, aficamten decreases left ventricular ejection fraction (LVEF); at Week 24, the mean change from baseline in LVEF was -7% in the aficamten group versus -2% in the placebo group.[L54788] The drug's effects are reversible: four weeks after discontinuation of treatment, LVEF and Valsalva LVOT-G returned to baseline.[L54788]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L54788]
Tmax ranges from 1.5 to 2.0 hours.
Aficamten is rapidly absorbed after oral administration. The bioavailability of aficamten after oral administration is unknown.
[L54788]
[L54788]
[L54788]
[L54788]
[L54788]
Inactive metabolites are further biotransformed via various reactions such as glucuronidation, sulfonation, microbiota-mediated reduction, and amide hydrolysis.
[A275313]
[L54788]
[L54788]
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Aficamten
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q106438207), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.